{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"description":"Change in Body Mass Index (BMI) in subjects from Baseline visit to 24 week visit.","dispersionType":"Standard Deviation","groups":[{"description":"Patients receive oral cyproheptadine hydrochloride twice daily for up to 24 weeks in the absence of weight loss or unacceptable toxicity.","id":"OG000","title":"Arm I- Cyproheptadine Hydrochloride"},{"description":"Patients receive oral cyproheptadine hydrochloride twice daily and oral PediaSure (2 to 10 years of age) or Ensure (\\> 10 years of age) twice daily for up to 24 weeks in the absence of weight loss or unacceptable toxicity.","id":"OG001","title":"Arm II Cyproheptadine HCl and PediaSure or Ensure"}],"paramType":"MEAN","reportingStatus":"POSTED","timeFrame":"24 weeks","title":"Body Mass Index as Assessed at Baseline and 24 Weeks","type":"SECONDARY","unitOfMeasure":"kg/m^2"}